To include your compound in the COVID-19 Resource Center, submit it here.

GeNeuro's GNbAC1 misses in Phase IIb for RRMS

GeNeuro S.A. (Euronext:GNRO) and Servier (Neuilly-sur-Seine, France) reported data from the 12-month Phase IIb CHANGE-MS trial in 270 patients with relapsing-remitting multiple sclerosis

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE